ClinicalTrials.gg
Not yet recruitingNCT07851389Updated Oct 1, 2026

A First-in-Human Feasibility Study of the Vibrant Stroke Detection Technology During Carotid Endarterectomies

An observational study in Carotid Stenosis, sponsored by Vibrant Medical Ltd.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Vibrant Medical Ltd. · Observational

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
10
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 84 studies in Carotid Stenosis with a site in United States — 6 open to participants now, 13 under way, none of them phase 3. Carotid Stenosis · United States.

Planned enrollment
30th of 31
10 · median 114
Started
2026
with 1 other
Observational
31 of 84
2 open now
Primary completion
2027-03
later than 6 of 12 live
Registered
83rd of 84
by date

Among the 84 studies in Carotid Stenosis with a site in United States, this one is the 30th largest by planned enrollment of the 31 observational ones that give a count, is one of 2 that started in 2026, is one of 31 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 83rd registered.

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

6 of the 84 studies in Carotid Stenosis with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Carotid Stenosis with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to learn whether continuous carotid artery blood flow signals can be recorded reliably during surgery, and whether Vibrant Medical's analysis method can detect measurable changes in those signals, in adults undergoing elective carotid endarterectomy (CEA). During CEA, the surgeon temporarily clamps the internal carotid artery as a routine part of the operation. This produces a brief, controlled and fully reversible stop in blood flow that resembles the blood flow change seen in a large-vessel ischemic stroke.

The main questions it aims to answer are:

  • Can usable, continuous blood flow signals be recorded from both sides of the neck before and during carotid clamping?
  • Do the recorded signals show consistent, repeatable changes that are time-locked to carotid clamping and release across patients?

Participants will have their scheduled surgery as usual. During surgery, two legally marketed, FDA-cleared diagnostic ultrasound systems will record blood flow from the common carotid artery on each side of the neck, before clamping, during clamping and after the clamp is released, for about 20 to 30 minutes in total. The recordings are analyzed later and are not seen or used by the surgical team. No part of the surgery or anesthesia care is changed, and there are no study visits after surgery.

Read the detailed description

Background

In-hospital stroke is often recognized late, because patients may be sedated, anesthetized or otherwise unable to report symptoms, and there is currently no cleared device that continuously monitors carotid blood flow to flag a sudden change. Vibrant Medical is developing a wearable, non-invasive ultrasound sensor for this purpose. The element that is first-in-human in this study is Vibrant Medical's analysis method (wave-intensity and bilateral-asymmetry processing of carotid Doppler signals), which has previously been applied only to benchtop flow-phantom and in-vivo ovine data.

Carotid endarterectomy provides a controlled clinical model for this first human evaluation: the internal carotid artery clamp is applied and released by the surgeon as part of standard technique, producing a time-stamped, reversible reduction in carotid flow with no additional risk to the patient.

Study design

This is a prospective, single-center, single-arm, observational feasibility study at Tampa General Hospital / University of South Florida. Signals are acquired with two legally marketed, FDA-cleared Class II diagnostic ultrasound systems, one per side, each used within its cleared Peripheral Vessel indication.

Recording phases

  1. Baseline (pre-clamp): 1 to 2 minutes of continuous recording after stable signal acquisition and before any clamping.
  2. Internal carotid artery clamping: recording from just before clamp application through 1 to 2 minutes of clamping.
  3. Planned non-recording interval: both transducers are removed during arteriotomy, plaque removal and closure.
  4. Reperfusion: transducers are re-applied after closure, if this does not delay the surgical team, and recording continues from before clamp release through 1 to 2 minutes of restored flow.

No surgical step, including clamp timing, is delayed, modified or made contingent on the recordings. If a stable signal is not available when the surgeon is ready, the case proceeds unchanged and the phase is documented as missed.

Data collection and analysis

A study coordinator records time stamps of transducer placement, clamp application and release, and each recording phase on a case report form. Blood pressure, heart rate and the standard-of-care neuromonitoring data for the case are extracted from the anesthesia record and time-stamped to surgical events. Demographic and clinical variables (such as age, sex, BMI, surgical side and ASA class) are abstracted from the medical record. Recordings are exported and analyzed offline by Vibrant Medical research software labeled For Research Use Only; no output is available to the clinical team. Results are summarized descriptively; this feasibility study is not powered for hypothesis testing.

03

Conditions studied

  • Carotid Stenosis

Browse trials for

Keywords

  • Carotid Endarterectomy
  • Stroke Detection
  • In-Hospital Stroke
  • Carotid Doppler Ultrasound
  • Wave Intensity Analysis
  • Continuous Hemodynamic Monitoring
  • First-in-Human
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (18 years or older) scheduled for elective unilateral carotid endarterectomy at Tampa General Hospital, identified by the treating surgical team from the elective operative schedule and approached during a routine pre-surgical encounter.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients 18 years of age or older.
  • Scheduled to undergo elective unilateral carotid endarterectomy.
  • Capable of providing written pre-operatively.
  • No condition precluding placement of an ultrasound transducer at either side of the neck, as determined by the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Emergency or urgent (non-elective) carotid endarterectomy.
  • Planned simultaneous bilateral carotid endarterectomy, which would prevent contralateral recording.
  • Known active neck wound, infection, or skin condition at the intended device application site.
  • Implanted active device at the neck (e.g., vagal nerve stimulator) that could be affected by external ultrasound.
  • Anatomy that prevents transducer contact at either side of the neck, as determined by the Investigator.
  • Enrollment in another interventional clinical study that could confound device performance assessment.
  • Pregnant patients, as determined by standard-of-care pregnancy testing performed prior to surgery.
  • Patients who, in the investigator's judgment, are unable or unlikely to comply with the protocol or to provide valid .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No

Groups and cohorts

  • Elective Carotid Endarterectomy Patients

    Adults undergoing elective unilateral carotid endarterectomy at Tampa General Hospital. Continuous bilateral common carotid Doppler signals are recorded intra-operatively at pre-clamp baseline, during internal carotid artery clamping, and at reperfusion, for approximately 20 to 30 minutes in total. Surgical and anesthesia care are not modified, and the recordings are not available to the clinical team.

    Device: Bilateral carotid Doppler signal acquisition (Vibrant Stroke Detection Technology)

Interventions

  • DeviceBilateral carotid Doppler signal acquisition (Vibrant Stroke Detection Technology)

    External, non-invasive recording of common carotid artery flow on both sides of the neck using two legally marketed, FDA-cleared Class II diagnostic ultrasound systems, one per side, each used within its cleared Peripheral Vessel indication: Telemed ArtUs EXT-2H with L12-5N40-A4 transducer (510(k) K211248) and Telemed SmartUs EXT-1M with L15-7L40H-5 transducer (510(k) K163121). Recordings are analyzed offline with Vibrant Medical research software (For Research Use Only). No output is shown to the surgical team and no clinical decision is based on the recordings.

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Successful Bilateral Carotid Signal Acquisition During Baseline and Internal Carotid Artery Clamping

    A subject is counted as a success when usable, continuous bilateral common carotid flow signal is acquired for the full duration of Phase 1 (pre-clamp baseline) and Phase 2 (internal carotid artery clamping), adjudicated against signal-quality criteria fixed before the first subject is enrolled. Subjects in whom acquisition fails are retained in the denominator. Reported as the percentage of enrolled subjects with an exact (Clopper-Pearson) 95% confidence interval, against a descriptive benchmark of at least 80%. This is not a hypothesis test. Phase 3 (reperfusion) is not part of this measure.

    Time frame: Intra-operative, from pre-clamp baseline through internal carotid artery clamping (single surgical encounter)

Secondary outcomes

  1. Percentage of Subjects With Successful Bilateral Carotid Signal Acquisition During Reperfusion

    Usable, continuous bilateral signal acquired for Phase 3, from before internal carotid artery clamp release through 1 to 2 minutes of restored flow. Reported descriptively and separately from the primary outcome, because both transducers are removed during the endarterectomy and re-application depends on not delaying the surgical team.

    Time frame: Intra-operative, from before clamp release through 1 to 2 minutes of reperfusion

  2. Carotid Flow Signal Characteristics Time-Locked to Internal Carotid Artery Clamp Application and Release

    Signal characteristics, including flow velocity, wave-intensity and bilateral-asymmetry measures, described per subject relative to the documented clamp application and release time stamps, and summarized descriptively. All enrolled subjects with any recorded data are included; no imputation is performed and missing phases are reported as missing.

    Time frame: Intra-operative, from pre-clamp baseline through reperfusion (single surgical encounter)

07

Study locations

1 site
  • Tampa General Hospital
    Tampa, Florida 33606, United States
    • Charles Briggs, MD · Principal investigator
    • Jean Bismuth, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data are coded, held under the data provisions of the clinical trial agreement, and are not planned for sharing. Aggregate study results will be made publicly available through publication or conference presentation.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.

Of 87 observational studies under Carotid Stenosis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 104. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Oct 1, 2026
StartEst.
Oct 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851389
Lead sponsor
Vibrant Medical Ltd.
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Oct 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Avennette Pinto
Contact
apinto3@usf.edu
813-505-4787
Charles Briggs, MD
principal investigator · Tampa General Hospital / University of South Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion